Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heptavalent botulinum antitoxin
- Development stage
- Unknown
- Lead developer
- Emergent BioSolutions
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Heptavalent botulinum antitoxin (HBAT), marketed under the brand name BAT, is an equine-derived polyclonal antibody preparation consisting of Fab and F(ab')2 fragments. It is indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in both adult and pediatric patients. Developed by Cangene (now Emergent BioSolutions) and approved by the US FDA in 2013, the antitoxin works by binding to and neutralizing circulating botulinum neurotoxins, thereby preventing their internalization into cholinergic nerve terminals and halting the progression of flaccid paralysis. It is currently stockpiled in the US Strategic National Stockpile (SNS) for emergency public health and biodefense use.
- Brand names
- BAT
- Other names
- Botulism Antitoxin HeptavalentBotulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)HBATHE-BATHFabBATequine-derived heptavalent botulinum antitoxin
02
Targets
BoNT/A (Botulinum neurotoxin type A)BoNT/B (Botulinum neurotoxin type B)BoNT/C (Botulinum neurotoxin type C)BoNT/D (Botulinum neurotoxin type D)BoNT/E (Botulinum neurotoxin type E)BoNT/F (Botulinum neurotoxin type F)BoNT/G (Botulinum neurotoxin type G)
Beyond the preview
Go deeper on heptavalent botulinum antitoxin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heptavalent botulinum antitoxin.